Skip to content

To see the efficacy of qurs musakkkin on increase blood pressure and comparision with telmisartan

A Clinical study on Zightudam Qawi Ibtidai ( Grade I Essential Hypertension ) and Comparative Evaluation of Qurs-e- Musakkin with Standard Control Drug Telmisartan in its Managament - ACSZQICEQM

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/074626
Enrollment
60
Registered
2024-10-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: qurs musakkin: 2 tab once a day for 60 days orally Control Intervention1: telmisarton: qurs musakkin Control Intervention2: Telmisarton 1 tab once a day qurs musakkin 2 tab once a day:

Sponsors

Department of Moalajat Ajmal Khan Tibbiya Collage Aligarh Muslim University Aligarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: clinically diagnosed patients of grade 1 essential hypertension (according to WHO/ISH,SBP-139-159 mmhg and DBP 90-99 mmhg on three consecutive visits unfer optimal condition with or without subjective parameters. patients of either sex patients in the age group of 35years to 60 years . no evidence of target organ damage. patients not taking any anti hypertensive drugs prior to state of treatment those who give written consent.

Exclusion criteria

Exclusion criteria: patients of severe and secondary hypertension. patients of below 35years and above 60 years. pregnant women and lactating mothers. patients with comorbid conditions like liver,kidney,or heart diseases. patients with clinical or laboratory evidence of target organ damage. patients of altered mental status. patients who do not sign informed concent form.

Design outcomes

Primary

MeasureTime frame
improvement in following criteria systolic bp dystolic bpTimepoint: two months with fortnightly follow uo

Secondary

MeasureTime frame
improvement in following criteria headache giddiness palpitation fatigueTimepoint: two months with fortnightly follow uo

Countries

India

Contacts

Public ContactNAVED AHMAD

Ajmal Khan Tibbiya College

drmursaleennaseer@gmail.com9412562724

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026